Comparison
Metformin vs Thymosin Alpha-1
Side-by-side of Metformin and Thymosin Alpha-1. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Metformin
Metformin for longevity: biguanide mechanism of action, TAME trial status, anti-aging dosage, weight loss data, life extension evidence in non-diabetics.
Thymosin Alpha-1
Thymosin alpha-1 peptide (Zadaxin, thymalfasin): 28-amino-acid TA1 immunomodulator. Dosing, T-cell effects, hepatitis B and HCV adjunct evidence.
Effects at a glance
Metformin
- •Reduces HbA1c by ~1.0 to 1.5 percentage points in type 2 diabetes; first-line agent in major guidelines
- •DPP trial: 31% reduction in T2DM incidence in adults with prediabetes over 2.8 years
- •Suppresses hepatic gluconeogenesis via AMPK activation and complex I inhibition
- •Long-term use depletes B12; annual monitoring recommended after year 2
- •Lifespan extension in non-diabetic humans is not established; TAME trial pending
- •MASTERS trial reported blunted resistance-training hypertrophy in older adults
Thymosin Alpha-1
- •28-amino-acid synthetic peptide identical to thymic-derived immunomodulator
- •Approved in over 35 countries as Zadaxin for hepatitis B, hepatitis C adjunct, and immune support
- •Not FDA approved in US; compounded by 503A/503B pharmacies for off-label immune support
- •Modulates T-cell maturation, NK activity, and Th1 polarization in immunocompromised states
- •Standard label dose: 1.6 mg subcutaneously twice weekly
- •Cleanest safety profile in the peptide class with hundreds of regulated trials behind it
Side-by-side
| Attribute | Metformin | Thymosin Alpha-1 |
|---|---|---|
| Category | pharmaceutical | peptide |
| Also known as | Glucophage, Fortamet, Glumetza, dimethylbiguanide | Talpha1, Ta1, Zadaxin, Thymalfasin |
| Half-life (hr) ↗ | 6 | 2 |
| Typical dose (mg) ↗ | 1500 | 1.6 |
| Dosing frequency | 1 to 3 times daily with meals; XR once daily | 2x weekly |
| Routes | oral | subcutaneous, intramuscular |
| Onset (hr) | 1 | 24 |
| Peak (hr) | 2.5 | 168 |
| Molecular weight | 129.16 | 3108.32 |
| Molecular formula | C4H11N5 | C129H215N33O55 |
| Mechanism | Suppresses hepatic gluconeogenesis primarily via AMPK activation and complex I inhibition; modestly improves peripheral insulin sensitivity and shifts gut microbiome composition. | Synthetic peptide modulator of innate and adaptive immunity. Promotes T-cell maturation and CD4/CD8 production, modulates Th1/Th2 balance, stimulates NK cell activity, and modulates TLR2/TLR9 signaling in dendritic cells. |
| Legal status | Prescription only (FDA approved for type 2 diabetes 1994) | Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List |
| WADA status | allowed | unknown |
| DEA / Rx | Rx only (not a controlled substance) | Rx only via international approval or US compounding (no controlled-substance schedule) |
| Pregnancy | Category B; used in gestational diabetes and PCOS per current guidance | Not recommended; insufficient data |
| CAS | 657-24-9 | 62304-98-7 |
| PubChem CID | 4091 | 16130571 |
| Wikidata | Q19484 | Q913854 |
Safety profile
Metformin
Common side effects
- nausea
- diarrhea
- abdominal discomfort
- metallic taste
- decreased appetite
- B12 depletion (long-term)
Contraindications
- eGFR below 30 mL/min/1.73m2
- acute or chronic metabolic acidosis
- severe hepatic impairment
- acute heart failure
- iodinated contrast within 48 hours
Interactions
- iodinated contrast media: renal injury risk; hold 48 hours peri-imaging(major)
- alcohol (heavy use): elevated lactic acidosis risk(major)
- cimetidine: raises metformin plasma levels via OCT2 inhibition(moderate)
- insulin and sulfonylureas: additive hypoglycemia risk in combination(moderate)
- dolutegravir: raises metformin exposure via OCT2(moderate)
Thymosin Alpha-1
Common side effects
- mild injection-site irritation (rare)
- transient mild fatigue (rare)
- occasional headache (rare)
Contraindications
- pregnancy
- lactation
- active organ transplant rejection therapy
- systemic immunosuppression for autoimmune disease (relative)
- severe active autoimmune disease (caution)
Interactions
- interferon-alpha: additive immune effect; used clinically in approved combination protocols(minor)
- calcineurin inhibitors (cyclosporine, tacrolimus): theoretical destabilization of immunosuppression; avoid(major)
- antimetabolites (azathioprine, mycophenolate): theoretical destabilization of immunosuppression; avoid(major)
- vaccine administration: may augment vaccine response in elderly or immunocompromised; coordinate with clinician(minor)
Which Should You Take?
Metformin and Thymosin Alpha-1 score evenly on the criteria we weight (goal breadth, legal accessibility, evidence depth). The conditionals below should drive the decision more than any aggregate score.
- → If your priority is metabolic health and glucose control, pick Metformin.
- → If your priority is healthspan extension, pick Metformin.
- → If your priority is immune support, pick Thymosin Alpha-1.
- → If your priority is post-training recovery, pick Thymosin Alpha-1.
Edge case: If you cannot self-administer injections, Metformin is the only oral option in this pair.
Default choice: either is defensible. Metformin edges out on goal breadth + legal accessibility; Thymosin Alpha-1 is the right call if your priority sits in the goals listed above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Metformin and Thymosin Alpha-1?
Metformin and Thymosin Alpha-1 differ in category (pharmaceutical vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Metformin or Thymosin Alpha-1?
Metformin half-life is 6 hours; Thymosin Alpha-1 half-life is 2 hours.
Can you stack Metformin with Thymosin Alpha-1?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper